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Background
Approximately 5–15% of patients with juvenile idio-
pathic arthritis belong to a subcategory of enthesitis
related arthritis (ERA), which is strongly associated with
HLA-B27 and male gender. Recent investigations have
suggested markedly low discontinuation rates of anti-
tumour necrosis factor (anti-TNF) agents in those with
ERA, in whom reports on long-term efficacy and safety of
anti-TNFs are still few.
Patients and methods
Based on Finnish register on biologic agents (ROB-FIN) in
children, assessment of efficacy was available in 12 male
patients with ERA, mean age being 13.6 years at anti-TNF
onset (range 8.9–17.3), mean duration of ERA 2.6 years
(range 0.2–6.3), and mean follow-up on anti-TNFs 18.5
months (range 6.0–70). All patients were receiving their
first course of anti-TNF agents; 7 infliximab, 4 etanercept,
and 1 adalimumab.
Results
At 3 months, 100% achieved ACR Pediatric 30% improve-
ment (ACR Pedi 30), 83% ACR Pedi 50, 83% ACR Pedi
70, and 17% ACR Pedi 100. At 6 months, these rates were
100%, 100%, 83%, and 17%; and at 12 months 100%,
100%, 83%, and 17%. Three patients achieved ARC Pedi
70 at 24 months, and one also at 60 and at 70 months.
No-one discontinued anti-TNFs due to adverse events
(AEs) or inefficacy. Two patients, one on etanercept and
another on infliximab, discontinued the therapy due to
clinical remission at 70 and 26 months, respectively. The
former relapsed within 6 weeks. Per 100 patient-years, 7.7
AEs and 0.45 serious AEs occurred.
Conclusion
Anti-TNF agents seem to be safe and highly effective in
ERA.
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